Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Elicio Therapeutics Inc (NQ: ELTX ) 5.180 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Elicio Therapeutics Inc Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering June 28, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Proposed Public Offering June 27, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P June 27, 2024 ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 05, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors January 25, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium January 17, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference January 16, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study January 11, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002 January 09, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces $7.0 Million Private Placement Financing December 22, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference December 04, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates November 09, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting November 03, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting October 11, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer September 27, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines September 07, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 06, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer September 05, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics August 28, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Reports Inducement Grants August 22, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates August 11, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model August 09, 2023 From Elicio Therapeutics Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.